X
skip to main content
Logo
News and Events

News and Press Releases

Here are the latest TFRI news stories. See our archive for a full history of news.

  • September 10, 2018

    Discovery of CD33 in human cord blood cells may affect design of targeted AML therapies

    This new discovery provides a possible explanation of why some trials that have used CD33 as a potential target for AML therapies have shown specific toxicities expected from a loss of normal stem cells.

  • September 10, 2018

    New discovery answers long-held question about myelodysplastic syndromes

    In a study published in Nature Communications (June 2018), a team led by Dr. Aly Karsan (BC Cancer) suggests that the key to understanding how both bone marrow failure and acute leukemia, two seemingly opposite conditions, can be caused by MDS lays in the loss of two microRNAs (143 and 145), which activates a signalling pathway in marrow blood cells called TGFβ that suppresses the creation of blood stem cells while expanding the number of slightly more mature progenitor cells being created in the bone marrow

  • September 10, 2018

    Co-targeting EphA2/A3 reduces rGBM tumour growth in mice models

    A bi-specific antibody created by a TFRI-funded team has shown great promise in reducing tumour growth in patients with recurrent glioblastoma (rGBM).

  • September 10, 2018

    How do doctors really feel about active surveillance?

    A new study asking health care professionals why many men with low-risk prostate cancer opt for invasive treatments instead of active surveillance reveals need for clearer guidelines and education on this safe management system.

  • September 10, 2018

    Team identifies CDC25 as a common therapeutic target for triple-negative breast cancer

    Targeting CDC25 could bring hope to patients with RB1-deficient triple-negative breast cancer (TNBC), according to Toronto-based TFRI-funded team.

  • September 10, 2018

    Deep-sea bacteria inspire researchers to develop new ways to see, treat tumours

    The novel dual-biomimetic system created by a TFRI-funded team could serve as a contrast agent that allows researchers to see tumours more clearly, while will also playing a role in photodynamic therapy (PDT), a promising treatment against cancer that uses light-activated drugs, called photosensitizing agents, to kill cancer cells.

  • September 10, 2018

    Scientists use protein found in mosquito virus to suppress RNAi pathway, opening door to make oncolytic viruses more effective

    By using a protein from a virus first found in Japanese mosquitoes in the 1950s, TFRI-funded researchers have discovered a new way to bypass antiviral responses in cancer cells, potentially making oncolytic viruses more effective.

  • September 10, 2018

    Upcoming Node Events and Cancellation of 2019 ASM

    We encourage members of our research community to Save the Date to participate/attend the planned regional node research events featuring talks and presentations by our funded investigators during the coming year.

  • August 03, 2018

    TFRI launches 2018 Terry Fox Run Challenge

    To register a team for the Terry Fox Run 2018, please visit http://www.terryfox.org/run/teams/, or join our TFRI Headquarters team captained by Dr. Victor Ling.

  • August 02, 2018

    Pilot project network teams report steady progress in first year of working together

    Over the past year, the Terry Fox Canadian Comprehensive Cancer Centre Network (TF4CN) has fostered unprecedented collaborations, harmonized complex research methods and created the basic framework for a digital platform that allows patient data to be shared, stored and analyzed.

Back to Top